Both IGF1 and IGF2 act through the tyrosine kinase insulin-like factor 1 receptor (IGF1R), which is widely overexpressed in multiple childhood sarcomas, including rhabdomyosarcomas [6–12], and other cancers such as breast cancer, prostate cancer and lung cancer [13–16]. This evidence concerns the gene IGF1R and breast carcinoma.